Insecticide-Treated Nets for the Prevention of Malaria in Pregnancy: A Systematic Review of Randomised Controlled Trials

Carol Gamble¹, Paul J. Ekwaru², Paul Garner³, Feiko O. ter Kuile³,⁴*

¹ Centre for Medical Statistics and Health Evaluation, University of Liverpool, Liverpool, United Kingdom, ² Clinical Epidemiology Unit, Makerere Medical School, Makerere University, Kampala, Uganda, ³ Liverpool School of Tropical Medicine, Liverpool, United Kingdom, ⁴ Malaria Branch, Division of Parasitic Diseases, United States Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Funding: The authors received no specific funding for this study.

Competing Interests: FOtK was co-author of two of the trials reviewed. No other conflicts of interest are declared.

Academic Editor: Stephen J. Rogerson, Royal Melbourne Hospital, Australia

Citation: Gamble C, Ekwaru PJ, Garner P, ter Kuile FO (2007) Insecticide-treated nets for the prevention of malaria in pregnancy: A systematic review of randomised controlled trials. PLoS Med 4(3): e107. doi:10.1371/journal.pmed.0040107

Received: June 29, 2006
Accepted: February 1, 2007
Published: March 27, 2007

Copyright: © 2007 Gamble et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: CI, confidence interval; EIR, entomological inoculation rate; G[Number], gravidity [number]; Hb, haemoglobin; HR, hazard ratio; IPT, intermittent preventive treatment; IPTp, intermittent preventive treatment in pregnancy; IPTp-SP, intermittent preventive treatment in pregnancy with sulfadoxine-pyrimethamine; ITN, insecticide-treated bednet; LBW, low birth weight; OR, odds ratio; RR, relative risk; SP, sulfadoxine-pyrimethamine; WHO, World Health Organization

* To whom correspondence should be addressed. E-mail: terkuile@liv.ac.uk

ABSTRACT

Background

Protection from malaria with insecticide-treated bednets (ITNs) during pregnancy is widely advocated, but evidence of benefit has been inconsistent. We undertook a systematic review of randomised trials.

Methods and Findings

Three cluster-randomised and two individually randomised trials met the inclusion criteria; four from Africa (n = 6,418) and one from Thailand (n = 223). In Africa, ITNs compared to no nets increased mean birth weight by 55 g (95% confidence interval [CI] 21–88), reduced low birth weight by 23% (relative risk [RR] 0.77, 95% CI 0.61–0.98), and reduced miscarriages/stillbirths by 33% (RR 0.67, 0.47–0.97) in the first few pregnancies. Placental parasitaemia was reduced by 23% in all gravidae (RR 0.77, 0.66–0.90). The effects were apparent in the cluster-randomised trials and the one individually randomised trial in Africa. The trial in Thailand, which randomised individuals to ITNs or untreated nets, showed reductions in anaemia and fetal loss in all gravidae, but not reductions in clinical malaria or low birth weight.

Conclusions

ITNs used throughout pregnancy or from mid-pregnancy onwards have a beneficial impact on pregnancy outcome in malaria-endemic Africa in the first few pregnancies. The potential impact of ITNs in pregnant women and their newborns in malaria regions outside Africa requires further research.

The Editors’ Summary of this article follows the references.
Introduction

Approximately 50 million pregnant women are exposed to malaria each year. Pregnant women are more susceptible to malaria, placing both mother and fetus at risk of the adverse consequences [1–3]. In areas of low and unstable transmission, such as in many regions in Asia and the Americas, women do not acquire substantial antimalarial immunity, and are susceptible to episodes of acute and sometimes severe malaria, and fetal and maternal death [4]. In areas with stable malaria transmission, such as in most of sub-Saharan Africa, infection with *Plasmodium falciparum* in pregnancy is characterised by predominantly low-grade, sometimes sub-patent, persistent or recurrent parasitaemia. These infections frequently do not result in acute symptoms yet are a substantial cause of severe maternal anaemia [5] and of low birth weight (LBW) [3], and as such are a potential indirect cause of early infant mortality [6–8]. Because most of these infections remain asymptomatic, and therefore undetected and untreated, prevention of malaria in pregnancy is especially important in these settings.

The World Health Organization (WHO) advocates a three-pronged approach to malaria control in pregnancy that includes the use of insecticide-treated bednets (ITNs), intermittent preventive treatment (IPT), and case management (treatment) [9]. In areas of stable malaria transmission in sub-Saharan Africa, ITNs are highly effective in reducing childhood mortality and morbidity from malaria [10]. Although ITNs are promoted as a major tool in the fight against malaria in pregnancy, the available evidence about their efficacy in pregnancy has been inconsistent. In this review, we summarise the available data from randomised controlled trials that compared the effects of ITNs to no nets, or to untreated nets, on the health of pregnant women and birth outcome.

Methods

A protocol was developed for this review [11], and the standard search strategy of the Cochrane Infectious Diseases Group was used to identify potentially relevant trials [12]. The inclusion criteria were all trials that randomised individuals (pregnant women) or clusters (community or antenatal clinics) in areas where malaria transmission occurs. Where cluster-randomised trials were identified, the methods of analysis were checked to ensure that the precision of the data extracted from the reports was correctly estimated. The authors needed to have adjusted for clustering, as ignoring the clustering provides the correct point estimate of the magnitude of the trial effect but may overestimate the precision, resulting in potentially incorrect conclusions [13]. Primary outcomes selected were mean haemoglobin and anaemia, and mean birthweight and LBW; secondary outcomes included peripheral malaria in the mother assessed by finger prick during pregnancy or at birth, placental malaria assessed by microscopy, clinical malaria, pre-term birth, fetal loss (defined as miscarriage or stillbirth), and maternal death.

Trial quality was assessed as adequate, inadequate, or unclear based on the methods used to generate the allocation sequence and allocation concealment [14]. Minimisation of loss to follow-up was considered adequate (≥90% of the participants randomised included in the analysis), inadequate (<90%), or unclear (not reported).

Outcomes were combined using the inverse variance method in RevMan [15,16]. We used the fixed-effects model throughout, and assessed heterogeneity by the I² test (with values of >50% representing moderate heterogeneity) [17]. To minimise the anticipated heterogeneity, no attempt was made to combine trials that compared ITNs to no nets and those that compared ITNs to untreated nets [10]. Because all the included studies from Africa compared ITNs to no nets, and one study comparing ITNs to untreated net was conducted in Thailand, this also resulted in stratification by the major malaria transmission regions (Africa versus non-Africa), which differ in transmission intensity, parasite species, predominant vector, and vector behaviour.

The effect of ITNs was expected to be greatest in the first few pregnancies because women develop pregnancy-specific immunity against placental parasites over successive pregnancies as a consequence of repeated exposure [18]. Because gravidity was considered the greatest potential modifier of the effect of ITNs, analyses were stratified a priori by gravidity groups whenever this was possible based on the details provided.

Other potential sources of effect modifications that were explored included concomitant use of IPT in pregnancy (IPTp), and differences between trials that used individual randomisation, in which women benefit primarily from personal protection by treated nets, and trials that used cluster randomisation. In the latter trials, ITNs were distributed to whole communities, which may result in a mass or community effect due to area-wide killing of the malaria-transmitting mosquitoes [19–21]. Women in the cluster-randomised trials were mostly provided with ITNs prior to becoming pregnant and were thus protected throughout pregnancy. In the individually randomised trials, nets were provided as part of antenatal care, i.e., typically from 20 to 24 wk onwards. We could not explore other potential sources of heterogeneity because the number of trials identified was too few.

Results

Description of Trials

Six trials were identified; we excluded one trial as the analysis had not adjusted for clustering, and loss to follow-up was high (Text S1) [22]. Of the five included trials (Table 1), two were individually randomised [23,24], and three were cluster-randomised with analysis that took design effects into account [25–27].

Four trials were conducted in stable malaria-endemic areas in Africa (three in Kenya [24,26,27] and one in northern...
| Trial        | Country   | Year of Study | Type of Trial | Quality | Unit of Randomisation | Sequence Generation | Concealment of Allocation | Inclusion of Participants | Comparison                              | Insecticide<sup>a</sup> | IPTp Policy | Participants | Transmission | Notes                                           |
|-------------|-----------|---------------|---------------|---------|-----------------------|---------------------|--------------------------|--------------------------|----------------------------------------|--------------------------|-------------|--------------|--------------|------------------------------------------------|
| Dolan et al. [23] | Thailand      | 1990–1992    | Individual Antenatal clinic attendee | Not described   | Not described                      | Adequate            | ITNs vs. untreated nets<sup>b</sup> | Permethrin               | None                        | All          | 341         | Low unstable transmission; P. falciparum and P. vivax; EIR 0.5/y | No-net group excluded<sup>c</sup> |
| Njagi et al. [24,29] | Kenya     | 1997–1999    | Individual Antenatal clinic attendee | Adequate        | Not described                      | Inadequate for delivery outcome | ITNs vs. no nets<sup>c</sup> | Cyfluthrin                | IPTp randomised<sup>d</sup> | G1 and G2    | 963         | Intense perennial; P. falciparum; EIR 60–300/y | Factorial design<sup>e</sup> |
| Browne et al. [25]   | Ghana       | 1994–1995    | Cluster Village (98) | Adequate         | Adequate                           | Inadequate for delivery outcome | ITNs vs. no nets       | Permethrin               | None                        | All          | 1,961       | Hyperendemic, perennial with marked seasonal variation; P. falciparum; EIR 100–300/y | Part of ITN child mortality trial |
| Shulman et al. [26] | Kenya       | 1994–1995    | Cluster Zone (56) | Adequate        | Adequate                           | Adequate for third trimester blood and for follow-up >4 wk after delivery | ITNs vs. no nets       | Permethrin               | None                        | G1           | 503         | Perennial with marked seasonal variation; P. falciparum; EIR 10/y | Part of ITN child mortality trial |
| ter Kuile et al. [27] | Kenya       | 1997–1999    | Cluster Village (79) | Adequate         | Adequate                           | Adequate            | ITNs vs. no nets       | Permethrin               | None                        | All          | 2,991       | Intense perennial; P. falciparum; EIR 60–300/y | Part of ITN child mortality trial |

<sup>a</sup>Permethrin at 500 g/m<sup>2</sup>.
<sup>b</sup>No-net group excluded from analysis because this group received untreated nets from a local non-governmental aid organisation during the study.
<sup>c</sup>Factorial design ITNs versus no nets and IPTp-SP versus placebo.

doi:10.1371/journal.pmed.0040107.t001
Insecticide-Treated Nets in Pregnancy

One trial included IPTp-SP in a factorial design [24]. Women were allocated to receive (1) ITNs plus IPTp-SP, (2) IPTp-SP alone, (3) ITNs plus IPTp-SP placebo, or (4) IPTp-SP placebo alone (“control”). None of the other trials included IPT.

In the four trials from Africa, only women having their first baby were included in one trial [26], women having their first or second baby in another [24], and women of all gravidity in the remaining two trials (Table 1) [25,27]. In the trials including pregnant women of all gravidity, the authors analysed them differently: ter Kuile et al. grouped by gravidity 1 to 4 (G1–G4) and gravidity 5 and above (G5+) [27]. Browne et al. grouped by first pregnancy (G1), second pregnancy (G2), and third pregnancy and above (G3+) for continuous endpoints [25]. To allow for sub-group analysis by gravidity group, we grouped the G3+ group from Browne et al. and the G5+ group from ter Kuile et al. into one subgroup, referred to as “high gravidity”, and the G1 from Shulman et al., the G1 and G2 groups from Browne et al. and

### Table 1

| Study or sub-category | Mean difference (g/L) | Weight % | Mean difference (g/L) | 95% CI |
|-----------------------|-----------------------|----------|-----------------------|--------|
| **01 In 3rd trimester- Low Gravidae** |                       |          |                       |        |
| Shulman 1998 G1       | 8.40                  | 3.50     | [8.50, 1.50]          |        |
| Browne 2001 G1, dry   | 8.40                  | 1.80     | [6.80, 2.00]          |        |
| Browne 2001 G1, wet   | 7.43                  | -1.40    | [-6.71, 3.91]         |        |
| Browne 2001 G2, dry   | 5.79                  | -3.20    | [-9.22, 2.82]         |        |
| Browne 2001 G2, wet   | 9.88                  | -1.70    | [-6.31, 2.91]         |        |
| **Subtotal (95% CI)** | 39.20                 | -0.03    | [2.26, -3.32]         |        |

Test for heterogeneity: Chi$^2$ = 4.25, df = 4 (P = 0.37), I$^2$ = 6.0%

Test for overall effect: Z = 0.03 (P = 0.98)

**02 In 3rd trimester- High Gravidae**

| Study or sub-category | Mean difference (g/L) | Weight % | Mean difference (g/L) | 95% CI |
|-----------------------|-----------------------|----------|-----------------------|--------|
| Browne 2001 G3+, dry  | 8.40                  | 3.80     | [-1.20, 1.80]         |        |
| Browne 2001 G3+, wet  | 16.80                 | -0.30    | [-3.84, 3.24]         |        |
| **Subtotal (95% CI)** | 25.20                 | 1.07     | [-3.95, 3.92]         |        |

Test for heterogeneity: Chi$^2$ = 1.72, df = 1 (P = 0.19), I$^2$ = 41.9%

Test for overall effect: Z = 0.72 (P = 0.47)

**03 At time of delivery- Low Gravidae**

| Study or sub-category | Mean difference (g/L) | Weight % | Mean difference (g/L) | 95% CI |
|-----------------------|-----------------------|----------|-----------------------|--------|
| Njagi 2002 G1-2, SP+  | 13.66                 | -2.00    | [-5.92, 1.92]         |        |
| Njagi 2002 G1-2, SP-  | 10.89                 | 3.00     | [-1.39, 7.39]         |        |
| ter Kuile 2003 G1-4   | 5.93                  | 6.00     | [0.05, 11.95]         |        |
| **Subtotal (95% CI)** | 30.18                 | 1.34     | [-3.97, 3.97]         |        |

Test for heterogeneity: Chi$^2$ = 5.69, df = 2 (P = 0.06), I$^2$ = 64.9%

Test for overall effect: Z = 1.00 (P = 0.32)

**04 At time of delivery- High Gravidae**

| Study or sub-category | Mean difference (g/L) | Weight % | Mean difference (g/L) | 95% CI |
|-----------------------|-----------------------|----------|-----------------------|--------|
| ter Kuile 2003 G5+    | 4.41                  | -3.80    | [-10.70, 3.10]        |        |
| **Subtotal (95% CI)** | 4.41                  | -3.80    | [-10.70, 3.10]        |        |

Test for heterogeneity: not applicable

Test for overall effect: Z = 1.08 (P = 0.28)

Total (95% CI)

| Study or sub-category | Mean difference (g/L) | Weight % | Mean difference (g/L) | 95% CI |
|-----------------------|-----------------------|----------|-----------------------|--------|
|                       | 100.00                | 0.50     | [0.95, 0.95]          |        |

Test for heterogeneity: Chi$^2$ = 13.91, df = 10 (P = 0.18), I$^2$ = 28.1%

Test for overall effect: Z = 0.67 (P = 0.50)

Figure 1. Effect of ITNs versus No Nets in Africa on Mean Haemoglobin Levels (in Grams/Litre)

The red squares represent the effect estimates of ITNs; the black lines represent the 95% confidence intervals associated with the effect estimates (a line with an arrow indicates that the confidence interval was greater than could be illustrated in the graph). The black diamonds represent the summary effect estimates for the different subgroups (“subtotal”) and for the overall effect (“total”). “Dry” and “wet” refer to the dry and wet seasons. SP+, women randomized to IPTp-SP; SP-, women randomized to receive placebo IPTp (factorial design).

doi:10.1371/journal.pmed.0040107.g001

Ghana [25]), all with entomological inoculation rate (EIR) > 11 y, and one in Karen refugee camps along the Thailand–Myanmar border in an area with low and markedly seasonal malaria where P. falciparum and P. vivax coexist (EIR 0.5/y) [23].

The African trials compared ITNs to no nets; 6,418 women were enrolled [24–27]. The remaining trial from Thailand randomised individual women to receive either ITNs, untreated nets, or no nets [23]. In the “no nets” arm, a large proportion of women received nets from another donor independent of the study, and the researchers split the results in this control arm into women using donor nets and women not using donor nets. Because this compromised the validity of the control arm, we included only the comparison of ITNs with untreated nets ($n = 223$).

All African trials gave double- or family-sized nets to each household. The nets used in Thailand were smaller single-sized nets (70 × 180 × 150 cm). All trials used the widely available insecticide permethrin (500 g/m²), except one trial that used cyfluthrin [24].

One trial included IPTp-SP in a factorial design [24]. Women were allocated to receive (1) ITNs plus IPTp-SP, (2) IPTp-SP alone, (3) ITNs plus IPTp-SP placebo, or (4) IPTp-SP placebo alone (“control”). None of the other trials included IPT.

In the four trials from Africa, only women having their first baby were included in one trial [26], women having their first or second baby in another [24], and women of all gravidity in the remaining two trials (Table 1) [25,27]. In the trials including pregnant women of all gravidity, the authors analysed them differently: ter Kuile et al. grouped by gravidity 1 to 4 (G1–G4) and gravidity 5 and above (G5+) [27]. Browne et al. grouped by first pregnancy (G1), second pregnancy (G2), and third pregnancy and above (G3+) for continuous endpoints [25]. To allow for sub-group analysis by gravidity group, we grouped the G3+ group from Browne et al. and the G5+ group from ter Kuile et al. into one subgroup, referred to as “high gravidity”, and the G1 from Shulman et al., the G1 and G2 groups from Browne et al. and
Table 2. Summary Effect Measures of Four Trials Comparing ITNs versus No Nets in Africa

| Endpoint Type | Measure | Number of Trials | Measure<sup>a</sup> | All Gravidity<sup>b</sup> | Low Gravidity<sup>b</sup> | High Gravidity<sup>b</sup> |
|---------------|---------|------------------|----------------------|--------------------------|-------------------------|-------------------------|
|               |         |                  | Trials | Effect<sup>a</sup> | 95% CI | p-Value | Trials | Effect<sup>a</sup> | 95% CI | p-Value | Trials | Effect<sup>a</sup> | 95% CI | p-Value |
| Continuous    | Haemoglobin (g/l) | 4 | Diff | [25–27,29] | 0.5 | −1.0 to 2.0 | 0.50 | [24–27] | 0.6 | −1.2 to 2.3 | 0.52 | [25,27] | 0.3 | −2.3 to 3.0 | 0.80 |
|               | Birth weight (grams)<sup>c</sup> | 4 | Diff | [24–27] | 33 | 5 to 62 | 0.02 | [24–27] | 55 | 21 to 88 | 0.001 | [25,27] | −20 | −74 to 33 | 0.45 |
| Dichotomous   | LBW (<2500 g)<sup>d</sup> | 3 | RR | [24–27] | 0.80 | 0.64 to 1.00 | 0.05 | [24–27] | 0.77 | 0.61 to 0.98 | 0.03 | [27] | 1.12 | 0.56 to 2.24 | 0.75 |
|               | Placental malaria (microscopy) | 1 | RR | [24,26,27] | 0.77 | 0.66 to 0.90 | 0.0009 | [24,26,27] | 0.78 | 0.66 to 0.92 | 0.003 | [27] | 0.72 | 0.48 to 1.08 | 0.12 |
|               | Pre-term delivery (<37 wk) | 3 | RR | [24,26,27] | 0.68 | 0.48 to 0.98 | 0.04 | [24,26,27] | 0.67 | 0.47 to 0.97 | 0.03 | [27] | 1.02 | 0.17 to 6.23 | 0.98 |
|               | Fetal loss (miscarriage/stillbirth) | 3 | RR | [24,26,27] | 0.68 | 0.48 to 0.98 | 0.04 | [24,26,27] | 0.67 | 0.47 to 0.97 | 0.03 | [27] | 1.02 | 0.17 to 6.23 | 0.98 |

<sup>a</sup>Effect measure obtained from fixed effect models. Diff, mean difference.

<sup>b</sup>Low gravidity indicates women of gravidity 1 or 2 (from [24–26, 29]) or 1–4 (from [27]); high gravidity indicates women of gravidity 3–5 (from [25]) or 5 (from [27]).

<sup>c</sup>Primary outcome.

<sup>d</sup>Haemoglobin levels during the third trimester or at the time of birth.

Browne et al. [25] provided sub-group analysis that was adjusted for the cluster design for continuous endpoints (birth weight, haemoglobin, and parasite densities) by primi- (G1), secundi- (G2), and multigravidae (G3+); dichotomised outcomes. Although proportions by gravidity group were provided, cluster-adjusted estimates of the precision of effect were available only for the overall effect and not by gravidity group.

doi:10.1371/journal.pmed.0040107.t002

Treated Nets versus No Nets (Four Trials in Africa)

Primary outcomes. All four trials reported the effect of ITNs on haemoglobin (Hb) levels and anaemia. Because of the variations in trial design and reporting, it was not possible to combine the results from all four trials for dichotomous endpoints. For continuous endpoints, they were not adjusted for cluster randomisation. Group C+G group from ter Kuile et al. into another sub-group Browne et al. referred to as 'Low gravidity' [25–27]. The study by Dolan et al. in Asia did not provide estimates by gravidity group with the exception of the effect on birth weight [28].
assessed in the third trimester (OR 0.88, 0.73–1.06, \( p = 0.19 \), two trials) [25,26] or at the time of delivery (RR 0.76, 0.67–0.86, \( p = 0.001 \), two trials) [24,27]. Placental malaria parasitaemia was lower with ITNs by 23% (95% CI 10–34, three trials; Table 2). There was no evidence for an effect on the prevalence of peripheral or placental malaria in women who were provided IPTp-SP (one trial, Figure 3) [24].

Geometric mean parasite densities in peripheral blood tended to be lower in the ITN groups in women having their first or second baby, although the result was not statistically significant (geometric mean ratio 0.82, 95% CI 0.66–1.02, \( p = 0.07 \), two trials) [24,25]. There was no evidence for a beneficial effect in women infected with malaria, the geometric mean parasite density was lower in the ITN group (507 versus 1,096, \( p = 0.049 \)), and anaemia (hematocrit, 30%) was less frequent with ITNs (RR 0.63, 95% CI 0.42–0.93). Mean birth weight was similar between the two groups (ITN group, 2,858 g, standard deviation 486, \( n = 94 \), versus untreated net group, 2,891 g, standard deviation 481, \( n = 85 \)), as was LBW (RR 1.04, 95% CI 0.52–2.07) and pre-term delivery (RR 0.92, 95% CI 0.45–1.88). Fetal loss was significantly lower in the ITN group (2/102, 2%) than the untreated net group (10/97, 10%) (RR 0.21, 95% CI 0.05–0.92). The number of maternal deaths was similar (ITN group, 0/103, versus untreated net group, 2/100).

The three trials reporting on fetal loss (miscarriage or stillbirth) showed a consistent reduction in fetal loss associated with ITNs in low gravidity women (33%, 95% CI 3–53, \( p = 0.03 \); Figure 4; Table 2). Browne et al. [25] did not provide a breakdown by intervention group.

Maternal death was reported by Njagi [24] (five deaths), with no trends evident by group; Shulman et al. [26] reported four deaths but did not specify the groups.

### ITNs versus Untreated Nets (One Trial from Thailand)

This trial was conducted on the Thailand-Myanmar border, with individual randomisation [23]. Fewer women experienced peripheral malaria parasitaemia in the ITN group, but this was not significant (RR 0.73, 95% CI 0.47–1.04); however, in women infected with malaria, the geometric mean parasite density was lower in the ITN group (507 versus 1,096, \( p = 0.049 \)), and anaemia (hematocrit < 30%) was less frequent with ITNs (RR 0.63, 95% CI 0.42–0.93). Mean birth weight was similar between the two groups (ITN group, 2,858 g, standard deviation 486, \( n = 94 \), versus untreated net group, 2,891 g, standard deviation 481, \( n = 85 \)), as was LBW (RR 1.04, 95% CI 0.52–2.07) and pre-term delivery (RR 0.92, 95% CI 0.45–1.88). Fetal loss was significantly lower in the ITN group (2/102, 2%) than the untreated net group (10/97, 10%) (RR 0.21, 95% CI 0.05–0.92). The number of maternal deaths was similar (ITN group, 0/103, versus untreated net group, 2/100).

---

**Table 2.** Effect of ITNs versus No Nets in Africa on Mean Birth Weight (in Grams)

| Study or sub-category | Mean difference (grams) | Weight % | Mean difference (grams) |
|-----------------------|-------------------------|----------|-------------------------|
| **01 Low Gravidae**   |                         |          |                         |
| Shulman 1998 G1       | 2.92                    | 0        | [-166, 166]              |
| Browne 2001 G1, dry   | 0.95                    | 100      | [-192, 392]             |
| Browne 2001 G1, wet   | 1.40                    | 160      | [-400, 80]              |
| Browne 2001 G2, dry   | 1.96                    | 50       | [-153, 253]             |
| Browne 2001 G2, wet   | 1.67                    | 140      | [-80, 360]              |
| Njagi 2002 G1-2, SP+  | 9.99                    | -30      | [-120, 60]              |
| Njagi 2002 G1-2, SP-  | 9.99                    | 70       | [-20, 160]              |
| ter Kuile 2003 G1-4   | 42.71                   | 78       | [34, 121]               |
| **Subtotal (95% CI)** |                         | 71.59    | 55 [21, 88]             |

Test for heterogeneity: \( \chi^2 = 8.74, df = 7 (P = 0.27), I^2 = 19.9\% \)

Test for overall effect: \( Z = 3.19 (P = 0.001) \)

| **02 High Gravidae** | Mean difference (grams) | Weight % | Mean difference (grams) |
|----------------------|-------------------------|----------|-------------------------|
| Browne 2001 G3+, dry | 0.54                    | -140     | [-527, 247]             |
| Browne 2001 G3+, wet | 1.40                    | 160      | [-80, 400]              |
| ter Kuile 2003 G5+   | 26.47                   | -27      | [-83, 29]               |
| **Subtotal (95% CI)** |                         | 28.41    | -20 [-74, 33]           |

Test for heterogeneity: \( \chi^2 = 2.59, df = 2 (P = 0.27), I^2 = 22.8\% \)

Test for overall effect: \( Z = 0.75 (P = 0.45) \)

| **Total (95% CI)** | Mean difference (grams) | Weight % | Mean difference (grams) |
|-------------------|-------------------------|----------|-------------------------|
|                   | 100.00                  | 33       | [5, 62]                 |

Test for heterogeneity: \( \chi^2 = 16.78, df = 10 (P = 0.08), I^2 = 40.4\% \)

Test for overall effect: \( Z = 2.30 (P = 0.02) \)

---

**Figure 2.** Effect of ITNs versus No Nets in Africa on Mean Birth Weight (in Grams)

The red squares represent the effect estimates of ITNs; the black lines represent the 95% confidence intervals associated with the effect estimates. The black diamonds represent the summary effect estimates for the different subgroups (“subtotal”) and for the overall effect (“total”). “Dry” and “wet” refer to the dry and wet seasons. SP+: women randomized to IPTp-SP; SP-, women randomized to receive placebo IPTp (factorial design).

doi:10.1371/journal.pmed.0040107.g002
**Discussion**

This systematic review shows that ITNs were associated with some important health benefits for pregnant women and their babies. Women of low gravidity randomised to ITNs delivered fewer LBW babies and were less likely to experience fetal loss (miscarriage or stillbirth). Although the latter was not a primary endpoint in the trials, it is an important outcome. No significant decrease was observed in pre-term deliveries in the single trial that assessed this outcome. The consistent reduction observed in the miscarriage and stillbirth rates suggests that the attributable effect of malaria on fetal loss may be underestimated in malaria-endemic Africa, where most women remain asymptomatic when infected with *P. falciparum*. Despite the reduction in malaria infections, no overall effect on mean haemoglobin was demonstrated, and data on maternal anaemia were inconsistent.

WHO currently recommends that women in malaria-endemic areas of Africa use both IPTp-SP and ITNs in pregnancy to prevent malaria. One of the two trials from western Kenya assessed the effect of ITNs and IPTp-SP simultaneously, using a factorial design. This trial showed that ITNs provided benefits in primigravidae when used alone, but it did not demonstrate additional benefits of the combined interventions over either of the single interventions [24,29].

The main benefit of ITNs in women protected by IPTp-SP may thus occur after birth through protection of infants from malaria, since infants typically share sleeping space with the mother for the first several months to years [30]. Similar considerations apply to the benefit of ITNs in grand-multiparous (G5+), as no direct beneficial effect on the developing fetus in terms of birth weight or fetal loss was apparent in this group.

The only trial included in this analysis that compared ITNs to untreated nets was also the only trial conducted outside of Africa, in an area with highly seasonal *P. falciparum* and *P. vivax* malaria on the Thailand–Myanmar border. It showed a statistically significant reduction in anaemia and fetal loss in all gravidae, but no evidence for a beneficial effect on birth weight or gestational age [23].

Extrapolation of results from the three cluster-randomised trials to predict the potential impact of programmes that distribute ITNs to individual pregnant women as part of antenatal care should be done with caution. Firstly, nets distributed as part of antenatal care will leave most women exposed to malaria in the first third or half of pregnancy, when the risk of peripheral malaria parasitaemia is greatest [3]. By contrast, most women in the cluster-randomised trials became pregnant after ITNs were distributed and were as such protected throughout pregnancy. Secondly, the effect of ITNs in the cluster-randomised trials reflects the combined effects of personal protection (individual barrier protection) and area-wide reductions in malaria transmission (community or mass effect) [19–21]. Extrapolation of the results from the cluster-randomised trials may thus be misleading.

**Figure 3. Effect ITNs versus No Nets in Africa on Placental Malaria**

The red squares represent the effect estimates of ITNs; the black lines represent the 95% confidence intervals associated with the effect estimates (a line with an arrow indicates that the confidence interval was greater than could be illustrated in the graph). The black diamonds represent the summary effect estimates for the different subgroups (“subtotal”) and for the overall effect (“total”). Placental malaria was defined as the presence of asexual parasitaemia detectable by microscopy. Data from Shulman et al. [26] are based on 25.8% of all enrolled women, and includes only women who delivered in the hospital. The degree of heterogeneity approached moderate levels ($I^2 = 49.9\%$) in the low gravidity group. Similar analysis using random instead of fixed-effect models gave a summary effect of 0.82 (0.61–1.11), 0.72 (0.48–1.08), and 0.79 (0.63–0.98) for low, high, and all gravidae, respectively. SP+, women randomized to IPTp-SP; SP−, women randomized to receive placebo IPTp (factorial design).

doi:10.1371/journal.pmed.0040107.g003
ITNs because women living in control households from adjacent villages not using ITNs will have benefited from the area-wide reductions in vector populations, as has been shown for effect estimates in young children [19]. Similar considerations apply to the trial comparing ITNs with untreated nets from the Thailand–Myanmar border [23]. Although, this trial randomised individual women, all trial participants lived in the same densely populated refugee camps and some mass effect by the treated nets cannot be excluded.

The most recent trial from western Kenya by Njagi et al. is informative in this respect, as it is the only trial that compared the effects of ITNs versus no nets using simple randomisation by individual in an area with low ITN coverage (little or no mass effect) [24,29]. This trial and the community-randomised trial by ter Kuile et al. [27] were conducted simultaneously in contiguous areas with similar malaria transmission at baseline, and similar socioeconomic and educational status and ethnicity of the trial population. The effect estimates were similar between the two trials (in women not randomised to IPTp-SP), suggesting that ITNs may work equally well when provided to individuals as part of antenatal care in the second trimester or when provided to entire communities.

The systematic review was informative, but there were some limitations stemming from the variety in trial designs and the number of trials. Outcome data were often expressed in different ways, and inclusion or analysis of gravidity groups was different. How anaemia and peripheral parasitaemia were detected and treated varied, with different periods of follow-up and different cut-offs, limiting our ability to provide summary estimates for some of the endpoints, or to provide sub-group analysis by gravidity group where desired.

Although relatively few trials have been conducted and some questions on the efficacy of ITNs in pregnant women in Africa remain, the four trials comparing ITNs with no nets suggest significant beneficial effects of ITNs on birth weight and fetal loss in the first few pregnancies in areas with moderate to intense malaria transmission in sub-Saharan Africa. These findings are consistent with a non-randomised trial of the effect of socially marketed ITNs conducted in an area with intense perennial malaria transmission in southern Tanzania [31], and with an excluded randomised controlled trial from The Gambia, which has lower and highly seasonal transmission [22]. These observed beneficial effects of ITNs during the first few pregnancies, together with the absence of

---

**Figure 4. Effect of ITNs versus No Nets in Africa on Miscarriage or Stillbirth**

The red squares represent the effect estimates of ITNs; the black lines represent the 95% confidence intervals associated with the effect estimates (a line with an arrow indicates that the confidence interval was greater than could be illustrated in the graph). The black diamonds represent the summary effect estimates for the different subgroups ("subtotal") and for the overall effect ("total").

Data from Shulman et al. [26] refer to stillbirths only. As the event is rare (<10%), the OR reported by Shulman et al. approximates an RR and has been combined with the RRs of Njagi [24] and ter Kuile et al. [27]; SP+, women randomized to IPTp-SP; SP-, women randomized to receive placebo IPTp (factorial design).

doi:10.1371/journal.pmed.0040107.g004

---

**Table 1: Studies and Results of Effect Estimates**

| Study or sub-category | Relative Risk (95% CI) | Weight (%) | Relative Risk (95% CI) |
|-----------------------|------------------------|------------|------------------------|
| **01 Low Gravidae**   |                        |            |                        |
| Shulman 1998 G1       | 8.06 0.67 [0.19, 2.34] |            |                        |
| Njagi 2002 G1-2, SP+  | 16.04 0.68 [0.28, 1.65] |            |                        |
| Njagi 2002 G1-2, SP-  | 25.39 0.64 [0.32, 1.29] |            |                        |
| ter Kuile 2003 G1-4   | 46.66 0.69 [0.41, 1.16] |            |                        |
| **Subtotal (95% CI)** | **96.15 0.67 [0.47, 0.97]** |            |                        |
| **Test for heterogeneity: Chi² = 0.03, df = 3 (P = 1.00), I² = 0%** | **Test for overall effect: Z = 2.14 (P = 0.03)** |            |                        |
| **02 High Gravidae**  |                        |            |                        |
| ter Kuile 2003 G5+    | 3.85 1.02 [0.17, 6.23] |            |                        |
| **Subtotal (95% CI)** | **3.85 1.02 [0.17, 6.23]** |            |                        |
| **Test for heterogeneity: not applicable** | **Test for overall effect: Z = 0.02 (P = 0.98)** |            |                        |
| **Total (95% CI)**    |                        |            |                        |
| **Test for heterogeneity: Chi² = 0.22, df = 4 (P = 0.99), I² = 0%** | **Test for overall effect: Z = 2.10 (P = 0.04)** |            |                        |
| **Data from Shulman et al. [26] refer to stillbirths only. As the event is rare (<10%), the OR reported by Shulman et al. approximates an RR and has been combined with the RRs of Njagi [24] and ter Kuile et al. [27]; SP+, women randomized to IPTp-SP; SP-, women randomized to receive placebo IPTp (factorial design).**

doi:10.1371/journal.pmed.0040107.g004

---

**Figure 4.** Effect of ITNs versus No Nets in Africa on Miscarriage or Stillbirth

The red squares represent the effect estimates of ITNs; the black lines represent the 95% confidence intervals associated with the effect estimates (a line with an arrow indicates that the confidence interval was greater than could be illustrated in the graph). The black diamonds represent the summary effect estimates for the different subgroups (“subtotal”) and for the overall effect (“total”).

Data from Shulman et al. [26] refer to stillbirths only. As the event is rare (<10%), the OR reported by Shulman et al. approximates an RR and has been combined with the RRs of Njagi [24] and ter Kuile et al. [27]; SP+, women randomized to IPTp-SP; SP-, women randomized to receive placebo IPTp (factorial design).

doi:10.1371/journal.pmed.0040107.g004
apparent harm to the developing fetus, the potential beneficial effect on the infant when the net continues to be used after birth [10], and the potential for ITNs to reduce malaria transmission through a mass killing effect on mosquito populations, support the current recommendations from WHO to provide ITNs for pregnant women in all regions with stable malaria transmission throughout sub-Saharan Africa, regardless of the degree of malaria transmission intensity.

Further evaluation of the potential effect of ITNs on pregnant women and their infants is warranted in malaria regions including the Americas, Asia, and the southwest Pacific, which represent approximately half of all pregnant women exposed annually to malaria. The more complex vector populations with exophagic, exophilic, and early biting behaviour in some of these areas may result in lower efficacy of ITNs than in Africa, where Anopheles gambiae s.s. is the most important vector. These studies should include women of all gravidae, and ideally address the interaction between ITNs and drug-based prevention such as IPTp, which is also largely untested outside of Africa. In Africa, it took over a decade for the evidence of ITN or IPTp efficacy in pregnant women to accumulate. It would be more efficient if trials had a common design, and if systematic reviews used individual patient data to allow appropriate collection of design effects, more accurate and standardised handling of the data, and more robust sub-group analysis. In order to enhance the rate at which evidence becomes available and is translated into policy, future trials would clearly benefit from better coordination between research groups.

**Supporting Information**

**Text S1.** QUOROM Flowchart

Screened, excluded, and included number of randomised controlled trials.

Found at doi:10.1371/journal.pmed.0040107.sd001 (24 KB PPT).

**Acknowledgments**

We thank Dr. Kiambo Njagi from the Ministry of Health, Nairobi, Kenya, and Prof. Pascal Magnusson from the Danish Bilharzia Laboratory, Copenhagen, Denmark, for provision of a copy of Dr. Njagi’s Ph.D. dissertation. PJE was supported by a Fellowship Programme grant from the Cochrane Infectious Diseases Group through the Effective Health Care Research Programme Consortium at the Liverpool School of Tropical Medicine, supported by the Department for International Development. FOtK was supported by a grant from WHO and the US Centers for Disease Control and Prevention.

This is an edited version of a Cochrane review available on the Cochrane Library 2006 disk issue 2[28]. Cochrane reviews are updated as new evidence emerges. The Cochrane Library should be consulted for the most recent version of the review.

**Author contributions.** PG coordinated the study. CG, PJE, and FOtK analyzed the data. FOtK and CG wrote the first draft, and all authors contributed to subsequent versions of the paper.

**References**

1. Stekete RW, Nahlen BL, Parise ME, Menendez C (2001) The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 64: 28–35.
2. Lindsay S, Ansell J, Selman C, Cox V, Hamilton K, et al. (2000) Effect of prophylaxis on exposure to malaria mosquitoes. Lancet 355: 1572.
3. Brabin BJ (1985) An analysis of malaria in pregnancy in Africa. Bull World Health Organ 61: 1005–1016.
4. Nosten F, Rogerson SJ, Beeson JG, McGready R, Mutabingwa TK, et al. (2004) Malaria in pregnancy and the endemcity spectrum: What can we learn? Trends Parasitol 20: 425–429.
5. Guyatt HL, Snow RW (2001) The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 64: 36–44.
6. van Geertruyden JP, Thomas F, Erhart A, D’Alessandro U (2004) The contribution of malaria in pregnancy to perinatal mortality. Am J Trop Med Hyg 71: 35–40.
7. Guyatt HL, Snow RW (2001) Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans R Soc Trop Med Hyg 95: 569–576.
8. Marchant T, Schellenberg JA, Nathan R, Abdulla S, Mukasa O, et al. (2004) Anaemia in pregnancy and infant mortality in Tanzania. Trop Med Int Health 9: 262–266.
9. World Health Organization Regional Office for Africa. (2004) A strategic framework for malaria prevention and control during pregnancy in the African region. WHO/AFO. AFMTAL/04.01. Brazzaville (Congol): World Health Organization Regional Office for Africa. Available: htp://www.who.int/malaria/tbm/Attachment/20040109/1 malaria_pregnancy_buildingblock_malaria_work.pdf. February 2006.
10. Lengeler C (2004) Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004: CD000563.
11. Ekwaru JP, Gambie C (2002) Insecticide-treated nets for preventing malaria in pregnancy. Cochrane Database Syst Rev 2002: CD003755. doi:10.1002/14651858.CD003755
12. Clarke M, Oxman A, editors (2003) Cochrane reviewers’ handbook, version 4.2.0. Oxford: Cochrane Collaboration.
13. Bland JM, Kerry SM (1997) Statistics notes. Trials randomised in clusters. BMJ 315: 600.
14. Juni P, Altman DG, Egger M (2001) Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 323: 42–46.
15. Woolf B (1955) On estimating the relation between two variables when each is subject to random error. Ann Hum Genet 19: 251–253.
16. Cochrane Collaboration (2003) Review Manager (RevMan), version 4 2 for Windows [computer program]. Oxford: Cochrane Collaboration.
17. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.
18. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE (1998) Maternal antibodies block malaria. Nature 395: 851–852.
19. Hawley WA, Phillips-Howard PA, ter Kuile FO, Terlouw DJ, Vulule JM, et al. (2003) Community-wide effects of permethrin-treated bed nets on child mortality and malaria morbidity in western Kenya. Am J Trop Med Hyg 68: 121–127.
20. Howard SC, Omonnho J, Nevill C, Some ES, Donnelly CA, et al. (2000) Evidence for a mass community effect of insecticide-treated bednets on the incidence of malaria on the Kenyan coast. Trans R Soc Trop Med Hyg 94: 357–360.
21. Binka FN, Indome F, Smith T (1998) Impact of spatial distribution of permethrin-impregnated bed nets on child mortality in rural northern Ghana. Am J Trop Med Hyg 59: 80–85.
22. D’Alessandro U, Langerock P, Bennett S, Francis N, Cham K, et al. (1996) The impact of a national impregnated bed net programme on the outcome of pregnancy in primigravidae in The Gambia. Trans R Soc Trop Med Hyg 90: 497–492.
23. Dolan G, ter Kuile FO, Jacoutot V, White NJ, Luxemburger C, et al. (1995) Bed nets for the prevention of malaria and anaemia in pregnancy. Trans R Soc Trop Med Hyg 87: 620–626.
24. Njagi JK (2002) The effects of sulfadoxine-pyrimethamine intermittent treatment and pyrethroid impregnated bed nets on malaria morbidity and birth weight in Bondo district, Kenya [dissertation]. Nairobi: University of Nairobi: Copenhagen: Danish Bilharzia Laboratory. 129 p.
25. Browne EN, Maude GH, Binka FN (2001) The impact of insecticide-treated bednets on malaria and anaemia in pregnancy in Kassa-Nankana district, Ghana: A randomized controlled trial. Trop Med Int Health 6: 467–476.
26. Shulman CE, Dorman EK, Talasma AO, Lowe BS, Nevill C, et al. (1998) A community randomized controlled trial of insecticide-treated bednets for the prevention of malaria and anaemia among primigravida in the Kenyan coast. Trop Med Int Health 3: 197–204.
27. ter Kuile FO, Terlouw DJ, Phillips-Howard PA, Hawley WA, Friedman JF, et al. (2003) Reduction of malaria during pregnancy by permethrin-treated bed nets in an area of intense perennial malaria transmission in western Kenya. Am J Trop Med Hyg 68: 50–60.
28. Gambie C, Ekwaru JP, ter Kuile FO (2006) Insecticide-treated nets for preventing malaria in pregnancy. Cochrane Database Syst Rev 2006: CD003755.
29. Njagi JK, Magnusson P, Estambale B, Ouma J, Mugo B (2003) Prevention of anaemia in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malarious area of Kenya: A randomized controlled trial. Trans R Soc Trop Med Hyg 97: 277–282.
30. ter Kuile FO, Terlouw DJ, Kariuki SK, Phillips-Howard PA, Mirel LB, et al. (2003) Impact of permethrin-treated bed nets on malaria, anaemia, and growth in infants in an area of intense perennial malaria transmission in western Kenya. Am J Trop Med Hyg 68: 88–77.
31. Marchant T, Schellenberg JA, Edgar T, Nathan R, Abdulla S, et al. (2002) Socially marketed insecticide-treated nets improve malaria and anaemia in pregnancy in southern Tanzania. Trop Med Int Health 7: 149–158.
Editors’ Summary

**Background.** Malaria is one of the world’s most important killer diseases. It is responsible for around a million deaths every year, most of them in Africa and most of them in children. Pregnant women and their unborn babies are also at high risk. Women who have malaria become extremely weak because of anemia, they are more likely to miscarry, and their babies have low birth weights. (Birth weights under 2.5 kilograms are considered to be low; low-birth-weight babies face higher risks of sickness and death than other babies.) It has been estimated that, every year, malaria during pregnancy is responsible for the deaths of about 100,000 to 200,000 babies within their first year of life.

The parasite that causes malaria is carried by certain species of mosquito. In the areas where these mosquitoes are found, taking steps to reduce the chance of being bitten can reduce one’s chances of getting infected with malaria. In Africa, these mosquitoes bite mainly in the hours of darkness, so sleeping under a mosquito net helps. During the last 20 years it has been established that mosquito nets impregnated with an insecticide provide much better protection than ordinary nets. Research has shown that children who sleep under these insecticide-treated nets (ITNs) are much less likely to get malaria than other children living in the same area. The correct use of ITNs is now being heavily promoted in many national and international programs.

**Why Was This Study Done?** It seems logical that pregnant women should be encouraged to sleep under ITNs, and this is recommended by the World Health Organization and other authorities. However, we cannot be sure that there are benefits, as there is a lack of clear evidence to show whether women who sleep under ITNs actually suffer less from malaria and anemia, and what the implications are for their babies.

**What Did the Researchers Do and Find?** They did no new work in the field or in the laboratory. Instead, they conducted what is known as a systematic review. Working to a set of criteria carefully formulated in advance, they searched the medical literature for well-conducted “randomized controlled trials” (RCTs) involving the use of ITNs by pregnant women. RCTs are studies where one group of people receives the “treatment” under investigation and another group does not. It is decided at random who goes into which group. The authors found five trials in Africa, four of which fulfilled the entry criteria for their analysis. In three of the four studies conducted in Africa, whole villages had been “randomized” to determine which pregnant women received ITNs. In another African trial, individual women had been randomized. In total, over 6,000 women were involved in the African trials. One trial had been done outside Africa, in Thailand, where just over 400 individual women had been randomized.

In the research done in Africa, it had been found that women who slept under ITNs had lower numbers of parasites in their blood. Miscarriages were much reduced—by a third in those women who were in their first few pregnancies. The overall proportion of babies who were low birth weight went down by nearly a quarter. In the research done in Thailand, the women using ITNs were less anemic and the miscarriage rate was again lower, although there was no change in the low-birth-weight figures.

**What Do These Findings Mean?** The evidence from the three trials done in Africa strongly suggests that it is a good idea for pregnant women to sleep under ITNs. With evidence available from only one trial conducted outside Africa, it is hard to be sure at this stage whether ITNs have the same beneficial effects for pregnant women in other parts of the tropics. More research is needed there.

**Additional Information.** The following organizations all have useful information about malaria on their Web sites, and we have provided links to the appropriate pages below. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0040107.

- US Centers for Disease Control and Prevention has information specifically about malaria during pregnancy
- Roll Back Malaria has information specifically about malaria during pregnancy
- Wikipedia—a free online encyclopedia that anyone can edit
- The World Health Organization (WHO)
- The United Nations Children’s Fund (UNICEF)
- MedlinePlus brings together authoritative information from the US National Library of Medicine, National Institutes of Health, and other government agencies and health-related organizations
- The Wellcome Trust